SCHEMBL4309806

SCHEMBL4309806

Cc1cc(C(=O)C(=O)c2ccc(F)c(OCCF)c2)ccc1OC(F)F

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 3/20 0.40
▸ REN P00797 2/20 0.40
▸ CTSD P07339 2/20 0.40
▸ BACE2 Q9Y5Z0 2/20 0.40
▸ PDE4B Q07343 8/20 0.39
▸ PDE4A P27815 7/20 0.39
▸ PDE4C Q08493 7/20 0.39
▸ PDE4D Q08499 7/20 0.39
▸ TTR P02766 4/20 0.39
▸ ALB P02768 1/20 0.39
▸ FFAR1 O14842 1/20 0.37
▸ FFAR4 Q5NUL3 1/20 0.37
▸ THRA P10827 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ TSHR P16473 1/20 0.36
▸ HTR2A P28223 1/20 0.36
▸ HTR2C P28335 1/20 0.36
▸ HTR2B P41595 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4309920 0.94 BACE1 (0.41) BACE1RENCTSDBACE2PDE4B
SCHEMBL4308405 0.89 REN (0.41) BACE1RENCTSDBACE2PDE4B
SCHEMBL4315262 0.88 TAS1R3 (0.47) BACE1RENCTSDBACE2PDE4B
SCHEMBL2797936 0.83 CES2 (0.44) BACE1RENCTSDBACE2PDE4B
SCHEMBL4304460 0.83 PDE4B (0.58) PDE4BPDE4APDE4CPDE4D
SCHEMBL4322471 0.83 TSHR (0.42) BACE1RENCTSDBACE2PDE4B
SCHEMBL4309410 0.82 CES2 (0.44) PDE4BPDE4APDE4CPDE4DTSHR
SCHEMBL4308383 0.81 BACE1 (0.41) BACE1RENCTSDBACE2PDE4B
SCHEMBL21387011 0.79 HDAC1 (0.46) BACE1PDE4BPDE4APDE4CPDE4D
SCHEMBL4313438 0.79 CES2 (0.40) BACE1RENCTSDBACE2PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137161-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2009-12-30 — — EP disclosed
US-20090042964-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS WYETH (US) 2009-02-12 — — US disclosed
WO-2008115552-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS WYETH (US) 2008-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042964-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS BACE1, BACE2, APP BACE1 1/4885REN 2367/4885CTSD 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback